Haruki Uojima

Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib

Haruki Uojima, Makoto Chuma, Yoshiaki Tanaka et al. · Liver Cancer · 2019 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase

Daniel Q. Huang, Andrew Tran, Ming‐Lun Yeh et al. · Hepatology · 2023 · 89 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Makoto Chuma, Haruki Uojima, Kazushi Numata et al. · Cancers · 2020 · 54 citations · Full text

Medicine, Oncology, Pharmacology +16

<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>

Katsuaki Ogushi, Makoto Chuma, Haruki Uojima et al. · Clinical and Experimental Gastroenterology · 2020 · 54 citations · Full text

Medicine, Oncology, Pharmacology +16

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

Taeang Arai, Masanori Atsukawa, Akihito Tsubota et al. · Hepatology Communications · 2022 · 51 citations · Full text

Medicine, Internal Medicine, Pharmacology +17